Silihan lan utang jangka dawa perusahaan: sxtchina.com (SXTC)

China SXT Pharmaceuticals (SXTC) generates revenue from the sale of herbal blends and medications for the domestic market. However, the high cost of innovation coupled with a lack of steady income leads to liquidity depletion and a search for external financing, which is recorded at the level of 0.53. This chart of the asset's value on the GURU.Markets platform complements the data regarding the vertically integrated production cycle of Chinese medicine.

This indicator captures the total volume of credit obligations with maturities exceeding one year, determining the issuer's long-term financial stability. Analyzing the long-term debt of China SXT Pharmaceuticals (SXTC) allows for the identification of hidden risks of overpaying for the asset by monitoring the borrowing rhythm. The metric aggregates all long-term liabilities, excluding short-term liquidity gaps. For China SXT Pharmaceuticals (SXTC), this is critical when procuring expensive botanical raw materials amid stringent government regulation of the PRC pharmaceutical market.